Francis H Glorieux

List of Publications by Year
in descending order

207 papers	23,746 citations	10373 72 h-index	7736 150 g-index
213 all docs	213 docs citations	213 times ranked	12802 citing authors

#	Article	IF	Citations
1	Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee. Journal of Bone and Mineral Research, 1987, 2, 595-610.	3.1	4,558
2	LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. Cell, 2001, 107, 513-523.	13.5	2,055
3	Osteogenesis imperfecta. Lancet, The, 2004, 363, 1377-1385.	6.3	1,084
4	Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta. New England Journal of Medicine, 1998, 339, 947-952.	13.9	889
5	Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Human Mutation, 2007, 28, 209-221.	1.1	620
6	CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta. Cell, 2006, 127, 291-304.	13.5	465
7	Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease. Journal of Bone and Mineral Research, 2000, 15, 1650-1658.	3.1	440
8	Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect. Journal of Bone and Mineral Research, 2002, 17, 30-38.	3.1	403
9	Targeted Inactivation of the 25-Hydroxyvitamin D3-1Î±-Hydroxylase Gene (CYP27B1) Creates an Animal Model of Pseudovitamin D-Deficiency Rickets*. Endocrinology, 2001, 142, 3135-3141.	1.4	358
10	Normative data for iliac bone histomorphometry in growing children. Bone, 2000, 26, 103-109.	1.4	302
11	The 25-Hydroxyvitamin D 1-Alpha-Hydroxylase Gene Maps to the Pseudovitamin D-Deficiency Rickets (PDDR) Disease Locus. Journal of Bone and Mineral Research, 1997, 12, 1552-1559.	3.1	290
12	Bone Response to Phosphate Salts, Ergocalciferol, and Calcitriol in Hypophosphatemic Vitamin D-Resistant Rickets. New England Journal of Medicine, 1980, 303, 1023-1031.	13.9	267
13	Deficient Mineralization of Intramembranous Bone in Vitamin D-24-Hydroxylase-Ablated Mice Is Due to Elevated 1,25-Dihydroxyvitamin D and Not to the Absence of 24,25-Dihydroxyvitamin D*. Endocrinology, 2000, 141, 2658-2666.	1.4	257
14	Perinatal metabolism of vitamin D. American Journal of Clinical Nutrition, 2000, 71, 1317S-1324S.	2.2	253
15	The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation, 2002, 110, 1293-1299.	3.9	231
16	Pamidronate Treatment of Severe Osteogenesis Imperfecta in Children under 3 Years of Age*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1846-1850.	1.8	230
17	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet, The, 2019, 393, 2416-2427.	6.3	229
18	Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate. Journal of Bone and Mineral Research, 2004, 19, 1779-1786.	3.1	226

#	Article	IF	Citations
19	Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4569-4575.	1.8	200
20	Use of Phosphate and Vitamin D to Prevent Dwarfism and Rickets in X-Linked Hypophosphatemia. New England Journal of Medicine, 1972, 287, 481-487.	13.9	195
21	Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Human Molecular Genetics, 1997, 6, 539-549.	1.4	184
22	Bisphosphonate Associated Osteonecrosis of the Jaw. Journal of Rheumatology, 2009, 36, 478-490.	1.0	173
23	Bone Mass, Size, and Density in Children and Adolescents With Osteogenesis Imperfecta: Effect of Intravenous Pamidronate Therapy. Journal of Bone and Mineral Research, 2003, 18, 610-614.	3.1	167
24	Increased Expression of the c-fosProto-Oncogene in Bone from Patients with Fibrous Dysplasia. New England Journal of Medicine, 1995, 332, 1546-1551.	13.9	166
25	Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV. Pediatrics, 2003, 111, 1030-1036.	1.0	165
26	Mutations in SERPINF1 cause osteogenesis imperfecta type VI. Journal of Bone and Mineral Research, 2011, 26, 2798-2803.	3.1	164
27	Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphatemic male mouse: Evidence for a defect in the brush border membrane. Kidney International, 1978, 14, 236-244.	2.6	163
28	Mutations in WNT1 are a cause of osteogenesis imperfecta. Journal of Medical Genetics, 2013, 50, 345-348.	1.5	162
29	Osteogenesis imperfecta. Best Practice and Research in Clinical Rheumatology, 2008, 22, 85-100.	1.4	146
30	Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2565-2573.	1.8	141
31	Osteogenesis Imperfecta: Update on presentation and management. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 153-160.	2.6	139
32	Collagen changes in the human uterine cervix at parturition. American Journal of Obstetrics and Gynecology, 1978, 130, 748-753.	0.7	137
33	The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation, 2002, 110, 1293-1299.	3.9	137
34	Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome. Journal of Bone and Mineral Research, 2005, 20, 1235-1243.	3.1	132
35	Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone, 2006, 39, 901-906.	1.4	130
36	Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 986-992.	1.8	127

#	Article	IF	Citations
37	InVitroMetabolism of 25-Hydroxycholecalciferol by Isolated Cells from Human Decidua*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 880-885.	1.8	120
38	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology, 2008, 35, 1391-7.	1.0	120
39	Vitamin D dependency: Replacement therapy with calcitriol. Journal of Pediatrics, 1981, 99, 26-34.	0.9	116
40	Safety Profile of Frequent Short Courses of Oral Glucocorticoids in Acute Pediatric Asthma: Impact on Bone Metabolism, Bone Density, and Adrenal Function. Pediatrics, 2003, 111, 376-383.	1.0	116
41	Evidence that Abnormal High Bone Mineralization in Growing Children with Osteogenesis Imperfecta is not Associated with Specific Collagen Mutations. Calcified Tissue International, 2008, 82, 263-270.	1.5	115
42	Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. Journal of Bone and Mineral Research, 2010, 25, 1367-1374.	3.1	109
43	Lumbar bone mineral content measured by dual energy Xâ€ray absorptiometry in newborns and infants. Acta Paediatrica, International Journal of Paediatrics, 1992, 81, 953-958.	0.7	108
44	Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in GÎ±s from patients with fibrous dysplasia of bone. Bone, 1997, 21, 201-206.	1.4	107
45	Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. Journal of Bone and Mineral Research, 2015, 30, 2150-2157.	3.1	107
46	BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. Journal of Bone and Mineral Research, 2017, 32, 1496-1504.	3.1	107
47	Dual Energy X-Ray Absorptiometry Measurement of Bone Mineral Content in Newborns: Validation of the Technique. Pediatric Research, 1992, 32, 77-80.	1.1	105
48	Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone, 2007, 40, 821-827.	1.4	104
49	Modern approach to children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics Part B, 2003, 12, 77-87.	0.3	102
50	Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of theIFITM5c.â^'14C>T mutation in all patients. Journal of Medical Genetics, 2013, 50, 21-24.	1.5	101
51	Histological Osteomalacia Due to Dietary Calcium Deficiency in Children. New England Journal of Medicine, 1982, 307, 584-588.	13.9	100
52	Pamidronate in Children with Osteogenesis Imperfecta: Histomorphometric Effects of Long-Term Therapy. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 511-516.	1.8	100
53	Rescue of the Pseudo-Vitamin D Deficiency Rickets Phenotype of CYP27B1-Deficient Mice by Treatment With 1,25-Dihydroxyvitamin D3: Biochemical, Histomorphometric, and Biomechanical Analyses. Journal of Bone and Mineral Research, 2003, 18, 637-643.	3.1	99
54	Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. Journal of Bone and Mineral Research, 2009, 24, 1282-1289.	3.1	98

#	Article	IF	Citations
55	Maternal and Fetal Outcome After Long-Term Pamidronate Treatment Before Conception: A Report of Two Cases. Journal of Bone and Mineral Research, 2004, 19, 1742-1745.	3.1	97
56	Pamidronate in Children and Adolescents with Osteogenesis Imperfecta: Effect of Treatment Discontinuation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1268-1274.	1.8	97
57	Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcified Tissue International, 1983, 35, 443-448.	1.5	96
58	Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. Journal of Pediatrics, 2006, 148, 456-460.	0.9	96
59	Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment. Bone, 2007, 40, 638-644.	1.4	94
60	Positive Linear Growth and Bone Responses to Growth Hormone Treatment in Children With Types III and IV Osteogenesis Imperfecta: High Predictive Value of the Carboxyterminal Propeptide of Type I Procollagen. Journal of Bone and Mineral Research, 2003, 18, 237-243.	3.1	93
61	Experience With Bisphosphonates in Osteogenesis Imperfecta. Pediatrics, 2007, 119, S163-S165.	1.0	93
62	Cole-Carpenter Syndrome Is Caused by a Heterozygous Missense Mutation in P4HB. American Journal of Human Genetics, 2015, 96, 425-431.	2.6	92
63	HRâ€pQCT Measures of Bone Microarchitecture Predict Fracture: Systematic Review and Metaâ€Analysis. Journal of Bone and Mineral Research, 2020, 35, 446-459.	3.1	92
64	Genotypeâ€“phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. European Journal of Human Genetics, 2010, 18, 642-647.	1.4	90
65	Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone, 2006, 39, 616-622.	1.4	88
66	Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13â€“14. Journal of Bone and Mineral Research, 1992, 7, 1447-1453.	3.1	88
67	Response to Crystalline 1Î±-Hydroxyvitamin D3 in Vitamin D Dependency. Pediatric Research, 1975, 9, 593-599.	1.1	80
68	Bone-Specific Expression of the Alpha Chain of the Nascent Polypeptide-Associated Complex, a Coactivator Potentiating c-Jun-Mediated Transcription. Molecular and Cellular Biology, 1998, 18, 1312-1321.	1.1	79
69	Osteoporosis Caused by Mutations in PLS3: Clinical and Bone Tissue Characteristics. Journal of Bone and Mineral Research, 2014, 29, 1805-1814.	3.1	78
70	Sclerotic Metaphyseal Lines in a Child Treated With Pamidronate: Histomorphometric Analysis. Journal of Bone and Mineral Research, 2004, 19, 1191-1193.	3.1	77
71	Intracortical remodeling during human bone developmentâ€”A histomorphometric study. Bone, 2007, 40, 274-280.	1.4	77
72	Deficient Bone Formation in Idiopathic Juvenile Osteoporosis: A Histomorphometric Study of Cancellous Iliac Bone. Journal of Bone and Mineral Research, 2010, 15, 957-963.	3.1	77

#	Article	IF	Citations
73	Deficient Mineralization of Intramembranous Bone in Vitamin D-24-Hydroxylase-Ablated Mice Is Due to Elevated 1,25-Dihydroxyvitamin D and Not to the Absence of 24,25-Dihydroxyvitamin D. Endocrinology, 2000, 141, 2658-2666.	1.4	77
74	Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. Journal of Bone and Mineral Research, 2013, 28, 2001-2007.	3.1	75
75	Serum 1,25-dihydroxyvitamin D concentration in hypophosphatemic vitamin D-resistant rickets. Calcified Tissue International, 1981, 33, 173-175.	1.5	74
76	Cyclical Intravenous Pamidronate Treatment Affects Metaphyseal Modeling in Growing Patients With Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2005, 21, 374-379.	3.1	72
77	Natural History of Hyperplastic Callus Formation in Osteogenesis Imperfecta Type V. Journal of Bone and Mineral Research, 2007, 22, 1181-1186.	3.1	71
78	Hypophosphatemic nonrachitic bone disease: An entity distinct from X-linked hypophosphatemia in the renal defect, bone involvement, and inheritance. American Journal of Medical Genetics Part A, 1977, 1, 101-117.	2.4	70
79	Interpretation of bone mineral density values in pediatric Crohn's disease. Inflammatory Bowel Diseases, 1998, 4, 261-267.	0.9	68
80	Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone, 2004, 35, 231-234.	1.4	68
81	Tooth Extraction Socket Healing in Pediatric Patients Treated with Intravenous Pamidronate. Journal of Pediatrics, 2008, 153, 719-720.	0.9	67
82	Replacement therapy for inherited enzyme deficiency: Liver orthotopic transplantation in Niemann-Pick disease type A. American Journal of Medical Genetics Part A, 1977, 1, 229-239.	2.4	66
83	Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone, 2002, 31, 19-25.	1.4	66
84	Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone, 2017, 95, 151-161.	1.4	66
85	Hypoparathyroidism during Pregnancy: Treatment with Calcitriol. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 810-813.	1.8	65
86	Homozygosity for Frameshift Mutations in XYLT2 Result in a Spondylo-Ocular Syndrome with Bone Fragility, Cataracts, and Hearing Defects. American Journal of Human Genetics, 2015, 96, 971-978.	2.6	65
87	Vitamin D metabolism in preterm infants: Serum calcitriol values during the first five days of life. Journal of Pediatrics, 1981, 99, 640-643.	0.9	64
88	Rapid Increase in Grip Force After Start of Pamidronate Therapy in Children and Adolescents With Severe Osteogenesis Imperfecta. Pediatrics, 2003, 111, e601-e603.	1.0	63
89	A Novel IFITM5 Mutation in Severe Atypical Osteogenesis Imperfecta Type VI Impairs Osteoblast Production of Pigment Epithelium-Derived Factor. Journal of Bone and Mineral Research, 2014, 29, 1402-1411.	3.1	63
90	Cortical and Trabecular Bone Density in X-Linked Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E954-E961.	1.8	62

#	Article	IF	Citations
91	Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations. Bone, 2014, 60, 122-128.	1.4	61
92	Osteogenesis imperfecta, current and future medical treatment. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2005, 139C, 31-37.	0.7	59
93	Lack of Circulating Pigment Epithelium-Derived Factor Is a Marker of Osteogenesis Imperfecta Type VI. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1550-E1556.	1.8	59
94	Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. Bone, 2014, 67, 56-62.	1.4	59
95	Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations â€" genotypeâ€"phenotype correlations and effect of bisphosphonate treatment. Bone, 2016, 86, 53-57.	1.4	58
96	The impact of severe osteogenesis imperfecta on the lives of young patients and their parents â€" a qualitative analysis. BMC Pediatrics, 2013, 13, 153.	0.7	57
97	Aging Versus Postmenopausal Osteoporosis: Bone Composition and Maturation Kinetics at Actively-Forming Trabecular Surfaces of Female Subjects Aged 1 to 84 Years. Journal of Bone and Mineral Research, 2016, 31, 347-357.	3.1	57
98	Bone mineralization and growth are enhanced in preterm infants fed an isocaloric, nutrient-enriched preterm formula through term. American Journal of Clinical Nutrition, 2004, 80, 1595-1603.	2.2	56
99	Osteotomy Healing in Children With Osteogenesis Imperfecta Receiving Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2015, 30, 1362-1368.	3.1	56
100	Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation. Journal of Bone and Mineral Research, 2017, 32, 1884-1892.	3.1	55
101	Muscle Anatomy and Dynamic Muscle Function in Osteogenesis Imperfecta Type I. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E356-E362.	1.8	54
102	The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V. Bone, 2006, 38, 13-20.	1.4	53
103	Cranial base abnormalities in osteogenesis imperfecta: Phenotypic and genotypic determinants. Journal of Bone and Mineral Research, 2011, 26, 405-413.	3.1	51
104	Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?. Annals of Medicine, 2005, 37, 295-302.	1.5	50
105	Interpretation of Bone Mineral Density Values in Pediatric CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 1998, 4, 261-267.	0.9	48
106	Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone. Bone, 2015, 73, 233-241.	1.4	48
107	Caffey disease: an unlikely collagenopathy. Journal of Clinical Investigation, 2005, 115, 1142-1144.	3.9	48
108	Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Reports, 2016, 5, 158-162.	0.2	47

#	Article	IF	Citations
109	The functional muscleâ€“bone unit in patients with osteogenesis imperfecta type I. Bone, 2015, 79, 52-57.	1.4	46
110	Perinatal Serum Bone Gla-Protein and Vitamin D Metabolites in Preterm and Fullterm Neonates*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 588-591.	1.8	45
111	Cellular Activity on the Seven Surfaces of Iliac Bone: A Histomorphometric Study in Children and Adolescents. Journal of Bone and Mineral Research, 2006, 21, 513-519.	3.1	45
112	Multidisciplinary Treatment of Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1834-1839.	0.5	45
113	Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations. Bone, 2014, 67, 63-70.	1.4	44
114	Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse. Calcified Tissue International, 1982, 34, 158-164.	1.5	42
115	Evaluation of the severity of malocclusions in children affected by osteogenesis imperfecta with the peer assessment rating and discrepancy indexes. American Journal of Orthodontics and Dentofacial Orthopedics, 2013, 143, 336-341.	0.8	41
116	The Muscle-Bone Relationship in X-Linked Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E990-E995.	1.8	41
117	Conventional and tissue-specific inactivation of the 25-hydroxyvitamin D-1Î±-hydroxylase (CYP27B1). Journal of Cellular Biochemistry, 2003, 88, 245-251.	1.2	40
118	Treatment of children with osteogenesis imperfecta. Current Osteoporosis Reports, 2006, 4, 159-164.	1.5	39
119	Pharmacokinetics and pharmacodynamics of a human monoclonal antiâ€FGF23 antibody (KRN23) in the first multiple ascendingâ€dose trial treating adults with Xâ€linked hypophosphatemia. Journal of Clinical Pharmacology, 2016, 56, 176-185.	1.0	38
120	High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone, 2005, 37, 634-641.	1.4	37
121	A polyadenylation site variant causes transcript-specific BMP1 deficiency and frequent fractures in children. Human Molecular Genetics, 2015, 24, 516-524.	1.4	37
122	Evidence for a Role for Nanoporosity and Pyridinoline Content in Human Mild Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2016, 31, 1050-1059.	3.1	36
123	Vitamin D/dietary calcium deficiency rickets and pseudo-vitamin D deficiency rickets. BoneKEy Reports, 2014, 3, 524.	2.7	35
124	Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2017, 32, 1034-1039.	3.1	35
125	Functional Analysis of Upper Limb Deformities in Osteogenesis Imperfecta. Journal of Pediatric Orthopaedics, 2004, 24, 689-694.	0.6	34
126	Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genetics in Medicine, 2019, 21, 275-283.	1.1	34

#	Article	IF	Citations
127	Rickets, the Continuing Challenge. New England Journal of Medicine, 1991, 325, 1875-1877.	13.9	33
128	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clinical Genetics, 2018, 94, 502-511.	1.0	33
129	Editorial: 24, 25-Dihydroxyvitamin Dâ€"Active Metabolite or Inactive Catabolite?. Endocrinology, 1998, 139, 3371-3374.	1.4	32
130	Activities and participation in young adults with Osteogenesis Imperfecta. Journal of Pediatric Rehabilitation Medicine, 2011, 4, 13-22.	0.3	32
131	Predictors and Correlates of Vitamin D Status in Children and Adolescents with Osteogenesis Imperfecta. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3193-3198.	1.8	32
132	Osteogenesis Imperfecta Type I Caused by COL1A1 Deletions. Calcified Tissue International, 2016, 98, 76-84.	1.5	32
133	Assessment of bone mineral content in infants: the new age. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 709-710.	0.7	31
134	Medical Therapy of Children With Fibrous Dysplasia. Journal of Bone and Mineral Research, 2006, 21, P110-P113.	3.1	30
135	In vivo osteogenic activity of isolated human bone cells. Journal of Bone and Mineral Research, 1991, 6, 45-51.	3.1	30
136	Osteogenesis Imperfecta Type VI in Individuals from Northern Canada. Calcified Tissue International, 2016, 98, 566-572.	1.5	30
137	Modern approach to children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics Part B, 2003, 12, 77-87.	0.3	29
138	Metaphyseal Dysplasia with Maxillary Hypoplasia and Brachydactyly Is Caused by a Duplication in RUNX2. American Journal of Human Genetics, 2013, 92, 252-258.	2.6	29
139	Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial. Bone, 2016, 86, 36-42.	1.4	29
140	Hyperplastic callus formation in osteogenesis imperfecta typeÂV: follow-up of three generations over ten years. Skeletal Radiology, 2008, 37, 465-467.	1.2	28
141	Vitamin D metabolism in rats with adjuvant-induced arthritis. Journal of Bone and Mineral Research, 1990, 5, 905-913.	3.1	28
142	Relationship between vitamin D status and bone mineralization, mass, and metabolism in children with osteogenesis imperfecta: Histomorphometric study. Journal of Bone and Mineral Research, 2011, 26, 2245-2251.	3.1	28
143	Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3516-3525.	1.8	28
144	Body Composition in Children and Adolescents with OsteogenesisÂImperfecta. Journal of Pediatrics, 2016, 169, 232-237.	0.9	28

#	Article	IF	Citations
145	Intestinal Phosphate Transport in Familial Hypophosphatemic Rickets. Pediatric Research, 1976, 10, 691-696.	1.1	27
146	Large Osteoclasts in Pediatric Osteogenesis Imperfecta Patients Receiving Intravenous Pamidronate. Journal of Bone and Mineral Research, 2009, 24, 669-674.	3.1	27
147	Shaping and managing the course of a child's disease: Parental experiences with osteogenesis imperfecta. Disability and Health Journal, 2014, 7, 343-349.	1.6	27
148	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified Tissue International, 2021, 108, 622-633.	1.5	26
149	Calcitriol treatment in vitamin D-dependent and vitamin D-resistant rickets. Metabolism: Clinical and Experimental, 1990, 39, 10-12.	1.5	25
150	Bone Mineralization in Polyostotic Fibrous Dysplasia: Histomorphometric Analysis. Journal of Bone and Mineral Research, 2002, 17, 1949-1953.	3.1	25
151	Low bone mass and high material bone density in two patients with Loeys-Dietz syndrome caused by transforming growth factor beta receptor 2 mutations. Journal of Bone and Mineral Research, 2012, 27, 713-718.	3.1	25
152	Role of the source of phosphate salt in improving the mineral balance of parenterally fed low birth weight infants. Journal of Pediatrics, 1990, 116, 765-772.	0.9	24
153	Panostotic fibrous dysplasia: A congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemia. American Journal of Medical Genetics Part A, 1983, 14, 725-735.	2.4	22
154	Circulating Sclerostin in Children and Young Adults with Heritable Bone Disorders. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E920-E925.	1.8	22
155	Targeted Sequencing of a Pediatric Metabolic Bone Gene Panel Using a Desktop Semiconductor Next-Generation Sequencer. Calcified Tissue International, 2014, 95, 323-331.	1.5	22
156	A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. JBMR Plus, 2019, 3, e10118.	1.3	22
157	Treatment of Osteogenesis Imperfecta: Who, Why, What?. Hormone Research in Paediatrics, 2007, 68, 8-11.	0.8	21
158	The effect of SERPINF1 in-frame mutations in osteogenesis imperfecta type VI. Bone, 2015, 76, 115-120.	1.4	21
159	Muscle Function in Osteogenesis Imperfecta Type IV. Calcified Tissue International, 2017, 101, 362-370.	1.5	19
160	Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study. American Journal of Medical Genetics, Part A, 2020, 182, 697-704.	0.7	17
161	Transport and metabolism of sarcosine in hypersarcosinemic and normal phenotypes. Journal of Clinical Investigation, 1971, 50, 2313-2322.	3.9	17
162	A disease of the osteoblast. Lancet, The, 2001, 358, S45.	6.3	16

#	Article	IF	Citations
163	Serum 24,25-Dihydroxyvitamin D Concentrations in Osteogenesis Imperfecta: Relationship to Bone Parameters. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1243-1249.	1.8	15
164	Osteogenesis Imperfecta, an Ever-Expanding Conundrum. Journal of Bone and Mineral Research, 2013, 28, 1519-1522.	3.1	15
165	Mobility in osteogenesis imperfecta: a multicenter North American study. Genetics in Medicine, 2019, 21, 2311-2318.	1.1	15
166	Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I. International Journal of Molecular Sciences, 2021, 22, 4508.	1.8	15
167	Intravenous Pamidronate in Osteogenesis Imperfecta Type VII. Calcified Tissue International, 2009, 84, 203-209.	1.5	14
168	Musculoskeletal phenotype in two unrelated individuals with a recurrent nonsense variant in SGMS2. Bone, 2020, 134, 115261.	1.4	14
169	Urinary Excretion of Cross-Linked N-Telopeptides of Type 1 Collagen to Assess Bone Resorption in Infants From Birth to 1 Year of Age. Pediatrics, 2002, 110, 105-109.	1.0	13
170	Aberrant splicing of the type III procollagen mRNA leads to intracellular degradation of the protein in a patient with ehlers-danlos type IV. Human Mutation, 1995, 6, 116-125.	1.1	12
171	Human 25-hydroxyvitamin D 24-hydroxylase cytochrome P450 subunit maps to a different chromosomal location than that of pseudovitamin D-deficient rickets. Journal of Bone and Mineral Research, 1993, 8, 1397-1406.	3.1	12
172	Ã‰tude dÃ©mographique et gÃ©nÃ©alogique de deux maladies hÃ©rÃ©ditaires au Saguenay. Cahiers QuÃ©bÃ©cois De DÃ©mographie, 1984, 13, 117-137.	0.5	11
173	Caries prevalence and experience in individuals with osteogenesis imperfecta: A crossâ€sectional multicenter study. Special Care in Dentistry, 2019, 39, 214-219.	0.4	11
174	Coneâ€Beam Computed Tomography of Osteogenesis Imperfecta Types III and IV: Threeâ€Dimensional Evaluation of Craniofacial Features and Upper Airways. JBMR Plus, 2019, 3, e10124.	1.3	11
175	Oro-dental and cranio-facial characteristics of osteogenesis imperfecta type V. European Journal of Medical Genetics, 2019, 62, 103606.	0.7	11
176	Effects of phosphate and 1,25(OH)2D3 on in vitro bone collagen synthesis in the hypophosphatemic mouse. Calcified Tissue International, 1983, 35, 383-391.	1.5	10
177	Renal Osteodystrophy in Children Treated with 1,25â€Dihydroxyâ€Cholecalciferol [1,25â€(OH)‹sub›2‹/sub›D‹sub›3‹/sub›]: Histologic Bone Studies. Acta Paediatrica, International Journal of Paediatrics, 1984, 73, 315-324.	0.7	10
178	Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder?. Bone, 2004, 35, 1023-1028.	1.4	10
179	Normal Bone Density and Fat Mass in HeterozygousSERPINF1Mutation Carriers. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2446-E2450.	1.8	10
180	Acetabular protrusion in osteogenesis imperfecta. Journal of Pediatric Orthopaedics, 2002, 22, 622-5.	0.6	10

#	Article	IF	Citations
181	Influence of vitamin D₃ states, phenobarbital, and diphenylhydantoin treatment on the plasma 25-hydroxyvitamin D₃ concentrations in the rat. Canadian Journal of Physiology and Pharmacology, 1981, 59, 1073-1081.	0.7	9
182	Title is missing!. Journal of Pediatric Orthopaedics, 2002, 22, 622-625.	0.6	9
183	Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height. Journal of Bone and Mineral Research, 2019, 34, 2198-2204.	3.1	9
184	Assessment of longitudinal bone growth in osteogenesis imperfecta using metacarpophalangeal pattern profiles. Bone, 2020, 140, 115547.	1.4	8
185	Predicting ambulatory function at skeletal maturity in children with moderate to severe osteogenesis imperfecta. European Journal of Pediatrics, 2021, 180, 233-239.	1.3	8
186	Involving Families with Osteogenesis Imperfecta in Health Service Research: Joint Development of the OI/ECE Questionnaire. PLoS ONE, 2016, 11, e0147654.	1.1	8
187	Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta. Calcified Tissue International, 2016, 98, 42-48.	1.5	7
188	Spondyloepimetaphysial Dysplasia with Joint Laxity in Three Siblings with B3GALT6 Mutations. Molecular Syndromology, 2017, 8, 303-307.	0.3	7
189	Osteogenesis imperfecta tooth level phenotype analysis: Cross-sectional study. Bone, 2021, 147, 115917.	1.4	7
190	Normal Serum 25-Hydroxyvitamin D Levels in Phenobarbital-Treated Toddlers. Developmental Pharmacology and Therapeutics, 1983, 6, 157-161.	0.2	6
191	Multisite longitudinal calibration of HR-pQCT scanners and precision in osteogenesis imperfecta. Bone, 2021, 147, 115880.	1.4	6
192	Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH). Orphanet Journal of Rare Diseases, 2022, 17, 30.	1.2	6
193	In vitro sulfate turnover in osteogenesis imperfecta congenita and tarda. American Journal of Medical Genetics Part A, 1979, 4, 349-355.	2.4	5
194	The collagen crosslinking in the hypophosphatemic male mouse. Calcified Tissue International, 1981, 33, 77-79.	1.5	5
195	Panostotic Fibrous Dysplasia A New Craniotubular Dysplasia. Clinical Nuclear Medicine, 1992, 17, 556-560.	0.7	5
196	Ã‰tiologie molÃ©culaire des rachitismes vitamino-dÃ©pendants hÃ©rÃ©ditaires. Medecine/Sciences, 2001, 17, 1289-1296.	0.0	4
197	Influence of Dietary Cholesterol on Vitamin D Metabolism in Formula-Fed Preterm Neonates. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, 180-184.	0.9	4
198	Treatment of children with osteogenesis imperfecta. Current Osteoporosis Reports, 2006, 4, 159-164.	1.5	3

#	Article	IF	Citations
199	Kinetic alterations in rat liver microsomal cholecalciferol 25-hydroxylase associated with phenobarbital administration. Biochemical Pharmacology, 1980, 29, 441-445.	2.0	2
200	Medical treatment of osteogenesis imperfecta. Drug Development Research, 2000, 49, 141-145.	1.4	2
201	Bisphosphonates in Osteogenesis Imperfecta. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 159-164.	1.3	2
202	LDL-Receptor Related Protein Five Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Obstetrical and Gynecological Survey, 2009, 64, 240-242.	0.2	2
203	Learning from the experience of a long-standing interprofessional osteogenesis imperfecta clinic: A case study evaluation. Journal of Interprofessional Education and Practice, 2017, 7, 54-60.	0.2	0
204	Perspectives on the evolution of genetic counselling: Experience over three decades in a family with recurrent lethal osteogenesis imperfecta. Molecular Genetics and Metabolism, 2020, 131, 114-115.	0.5	0
205	Lung Transplantation in a Patient With Osteogenesis Imperfecta and Osteoporosis. Journal of the Endocrine Society, 2021, 5, A205-A205.	0.1	0
206	OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH). Journal of the Endocrine Society, 2019, 3, .	0.1	0
207	Emerging concepts in pediatric bone disease. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 346.	1.2	0